• AR and ARv7 in TNBC: Prognostic Value and Enzalutamide Modul

  2026-08-03

  This study investigates the clinical relevance of androgen receptor (AR) and its splice variant ARv7 in triple-negative breast cancer (TNBC), highlighting their association with poor prognosis and metastasis. The authors demonstrate that targeting AR/ARv7 with Enzalutamide or EPI-001 in MDA-MB-231 cells suppresses key metastatic and EMT pathways, providing a mechanistic rationale for AR-directed interventions in TNBC models.

• 1,2-Dioleoyl-sn-glycero-3-PE (DOPE): Reliable Lipid Solution

  2026-08-02

  Discover how 1,2-Dioleoyl-sn-glycero-3-PE (DOPE) (SKU C4956) addresses persistent challenges in nucleic acid delivery, endosomal escape, and lipid nanoparticle formulation. This article delivers scenario-driven, evidence-based strategies for optimizing cell viability and transfection assays, while benchmarking supplier quality and workflow compatibility.

• Aprotinin in Experimental Workflows: Precision Protease Inhi

  2026-08-01

  Harnessing aprotinin’s reversible, potent serine protease inhibition unlocks new precision in blood management, inflammation research, and nascent RNA profiling. This article provides actionable protocol enhancements, troubleshooting insights, and bridges the latest methodological advances in genomics and cardiovascular science.

• Targeted CRISPRi Delivery to Adipocytes Ameliorates Obesity

  2026-07-31

  This study demonstrates a novel targeted, nonviral CRISPR interference (CRISPRi) delivery system that selectively silences Fabp4 in white adipocytes, leading to significant reductions in obesity, inflammation, hepatic steatosis, and insulin resistance in vivo. The approach offers a safer and more effective alternative to conventional anti-obesity therapies, with high translational potential for metabolic disorder research.

• Transforming inv(16) AML Research: AI-10-49 and the N-MYC/eI

  2026-07-31

  Explore how AI-10-49, a selective leukemia oncoprotein CBFβ-SMMHC inhibitor, is reshaping acute myeloid leukemia research by disrupting pivotal protein interactions and restoring transcriptional control. This article integrates mechanistic insight, experimental validation, and strategic guidance for translational researchers aiming to advance interventions targeting the N-MYC/eIF4G1 pathway in inv(16) AML.

• Optimized hiPSC Platelet Production via Small Molecule Modul

  2026-07-30

  This study presents a systematically optimized protocol for deriving functional platelets from human induced pluripotent stem cells (hiPSCs), leveraging small molecule modulators to enhance yield and maturation. The findings provide a cost-effective, scalable approach with implications for transfusion medicine and cellular therapy.

• TAK-242 (Resatorvid): Reliable TLR4 Inhibition for Cell Assa

  2026-07-30

  This article guides biomedical researchers through real-world challenges in cell viability and inflammatory assays, focusing on TAK-242 (Resatorvid), a selective Toll-like receptor 4 (TLR4) inhibitor (SKU A3850). Scenario-driven Q&A blocks illustrate how TAK-242 empowers reproducible, pathway-specific cytokine suppression and neuroinflammation research. Practical protocol tips and literature-backed data help optimize experimental outcomes with TAK-242 from APExBIO.

• Berberine Inhibits SASP Inflammation via RXRα/PPARγ/NEDD4 Ax

  2026-07-29

  This study delineates how berberine attenuates SASP-driven inflammation in atherosclerosis by activating the RXRα/PPARγ/NEDD4 signaling pathway. The mechanistic insights offer new perspectives for targeting vascular inflammatory aging and refining tools for dissecting PPARγ-mediated processes.

• NUAK1/2 Inhibition Reduces Pathological Tau in Alzheimer’s M

  2026-07-29

  Taylor et al. (2023) establish that phosphorylation of tau at serine 356 by NUAK1 is closely linked to Alzheimer’s disease pathology, and demonstrate that the selective NUAK1/2 inhibitor WZ4003 specifically reduces this modification in mouse and human brain tissue. These findings highlight the potential for targeting NUAK1/2 to modulate disease-relevant tau species and inform future therapeutic strategies.

• Catalpol’s Neuroprotective Mechanisms in Alzheimer’s Disease

  2026-07-28

  The referenced study systematically reviews how catalpol, an iridoid glycoside from Rehmannia glutinosa, exerts neuroprotective effects in Alzheimer’s disease (AD) models through antioxidant, anti-inflammatory, and antiapoptotic mechanisms. Its multitarget actions and safety profile highlight the promise of natural compounds for developing novel interventions against AD.

• DiscoveryProbe FDA-approved Drug Library in High-Throughput

  2026-07-28

  The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) unleashes rapid, reproducible screening of 2,320 clinically approved compounds for drug repositioning and target validation. Its ready-to-use, HTS-optimized formats directly accelerate the discovery of novel pharmacological chaperones and therapeutic candidates across diverse disease models.

• IPR-803: Transforming Stromal Modulation in Pancreatic Cance

  2026-07-27

  Explore IPR-803, a pioneering urokinase receptor inhibitor, and its unique role in stroma-targeted pancreatic cancer research. This article unpacks advanced mechanisms, novel nanomedicine strategies, and protocol guidance, offering a deeper scientific lens beyond standard applications.

• Cholesterol Impedes Intracellular Trafficking of Lipid Nanop

  2026-07-27

  This study uncovers how elevated cholesterol levels in lipid nanoparticles (LNPs) hinder their intracellular trafficking by promoting aggregation in peripheral early endosomes. The findings have significant implications for optimizing LNP formulations for nucleic acid delivery, guiding future strategies to enhance therapeutic cargo release.

• EZ Cap™ Human PTEN mRNA (ψUTP): Mechanism and Research Bench

  2026-07-26

  EZ Cap™ Human PTEN mRNA (ψUTP) is a Cap1-structured, pseudouridine-modified in vitro transcribed mRNA designed for robust PTEN expression, mRNA stability enhancement, and suppression of RNA-mediated innate immune activation. This article details its molecular rationale, mechanism, and current research benchmarks in cancer models, emphasizing its translational impact and practical workflow parameters.

• Optimizing Assays with 10 mM dNTP (2'-deoxyribonucleoside-5'

  2026-07-25

  This scenario-driven guide explores how the 10 mM dNTP (2'-deoxyribonucleoside-5'-triphosphate) Mixture (SKU K1041) resolves real laboratory challenges in DNA synthesis, PCR, and cell-based assays. Drawing on validated protocols and literature, biomedical researchers and lab technicians will find evidence-based answers to assay reproducibility and workflow reliability with this essential DNA synthesis reagent.

548 records 9/37 page Previous Next First page 上5页 678910 下5页 Last page